Table 2 Clinical characteristics of patients with invasive MRSA infections
| Â | Antibiotic use | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Vancomycin | Linezolid | Fosfomycin | β-lactam | ||||||
Single drug | +β-lactam | +Isepamicin | Single drug | +fosfomycin | +β-lactam | Single drug | +β-lactam | Single drug | |
Sepsis (n = 58) |  |  |  |  |  |  |  |  |  |
 Primary Sepsis (n = 18) | 5 | 11 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
 Sepsis with pneumonia (n = 25) | 2 | 12 | 0 | 8 | 1 | 2 | 0 | 0 | 1 |
 Sepsis with SSTI (n = 7) | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 Sepsis with bone and joint infections (n = 3) | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 Sepsis with CNS infections (n = 2) | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 Sepsis with pneumonia and CNS infections (n = 2) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
 Sepsis with pneumonia and bone and joint infections (n = 1) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Pneumonia (n = 5) | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Bone and joint infections (n = 2) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
CNS infection (n = 1) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Peritonitis (n = 1) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Treatment success rate (%) | 86.7% (13/15) | 91.7% (33/36) | 0.0% (0/1) | 100.0% (9/9) | 0.0% (0/1) | 100.0% (4/4) | 0.0% (0/0) | 0.0% (0/1) | 0.0% (0/2) |